Background: To retrospectively analyze the efficacy and prognostic factors of ectinib hydrochloride alone or combined with brain radiotherapy in the treatment of brain metastases from NSCLC with EGFR mutation, so as to provide a reference for more accurate evaluation of prognosis and selection of the best treatment modality. Method: Total of 85 patients were enrolled from Oct/2014 to Oct/2017 in JLCH who pathologically diagnosed or cytology for NSCLC with EGFR mutations and had developed brain metastases. All the 85 patients were adenocarcinoma. 51 patients received with icotinib combined radiotherapy. 34 patients received with Icotinib alone, 15 patients took loca lesion radiotherapy, 11 patients took whole brain radiation therapy, 25 patients took whole brain radiation therapy and plus dose. SPSS22.0 was applied for survival analysis with Kaplan-Meier method and categorical data with chi-square test. COX model for multiple factors analysis. Logistic method for RR and DCR multi-factor analysis. Results: The total iORR is 64.6%, the iDCR is 95.3%. For the group of icotinib alone, iCR is 5 (14.7%), iPR is 14 (41.2%), iSD is 10 (29.4%), and iPD is (14.7%). iORR is 55.9%, iDCR is 85.2%. For the group of icotinib combined radiotherapy, iCR is 5 (9.8%), iPR is 29 (56.9%), iSD is 17 (33.3%). iORR is 66.7%, iDCR is 100%. There were statistical difference for iDCR between two groups (c 2 ¼7.698, P¼0.022). Logistic model multi-factor analysis results: the surgery history of pulmonary lesion, Update-GPA grading scale and the number of metastasis organs were OS independent factors, the time to brain metastasis, mutation type and Update-GPA grading scale were PFS independ-ent factors, the time to brain metastasis, mutation type and Update-GPA grading scale were iPFS independent factors. The iDCR of the group of loca lesion radiotherapy, the whole brain radiation therapy and local acceleration were 100%, the iORR is 53.8%, 77.8%, 70.0%. The iDCR of the group of the early involvement of radiotherapy is 100%, the iORR is 77.8%, 46.7%, there were statistical difference between two groups (c 2 ¼4.200, P¼0.040). Conclusion: 1. The use of Icotinib to EGFR mutant NSCLC patients with brain metastases have a higher intracranial objective response rate, prolonged survival significantly. 2. The history of pulmonary lesion surgery, update-GPA grading scale and the number of metastasis organs were OS independent factors, the time to brain metastasis, mutation type and update-GPA grading scale were PFS and iPFS independent factors. 3. The participation of brain radiotherapy can increase iDCR. The early participation of brain radiotherapy can increase iORR. Keywords: Non-small cell lung, brain metastasis, Brain metastasis radiotherapy, Target therapy FirstJiLinU, Changchun/CN, 2 First Affiliated Hospital, Jilin University, Changchun/CN Background: Lung adenocarcinoma is an evolutional disease, which includes different stages such as atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA) , and invasive adenocarcinoma (IA) ,which all can occur independently with each other. However, whether these primary tumors exist synchronous or successively in just one individual. What is the major factor to drive a focus developing from AAH (benigh) to MIA or IA (malignant). In this study, we reported a case with AAH, MIA, and IA to understand and recognize this kind of disease, and to explore the gene heterogeneities among these focuses. Method: XXX, female, 50 years old，non-smoker,whose chest CT suggested two nodules in the right upper lobe, sized 1 cm and 0.5 cm, respectively .Surgical resection in the upper lobe of the right lung was performed for her. Postoperative pathology confirmed that these two nodules were IA and MIA, respectively. Besides those, a third more nodule, which was AAH was found in the deeper resectional lung tissue which had not been found in the chest CT scan. We then performed whole-exome sequencing (WES) to analyze the details of gene information. Results: Sequencing data showed that there was no obvious overlap among these three nodules, we listes the major gene information in Figure 1 . We found that EGFR mutation was just observed in the nodule with IA, but not in MIA or AAH. Conclusion: AAH, MIA, and IA are different evolutional stages of lung adenocarcinoma. Different gene information existing in these different pathologies made them highly heterogenous. EGFR should be the major driver gene which could be observed just in IA, but not in the earlier evolutional stage. More sequencing data is needed to verify our findings. Keywords: heterogenous, Pathology, lung adenocarcinoma, whole-exome sequencing (WES)
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